Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

European Medicines Agency stories

Jul 24, 2026

EU Regulator Backs First Oral IL-23 Receptor Drug for Plaque Psoriasis

The European Medicines Agency has recommended granting marketing authorization for Icotyde (icotrokinra), the first oral medication targeting the interleukin-23 receptor, for treating moderate-to-severe plaque psoriasis in adults and adolescents aged 12 years and older in the European Union.

Jul 24, 2026·1 source
00

Top claims

  • ▪Janssen-Cilag International N.V. is the applicant for the marketing authorisation of Icotyde.
  • ▪The Committee for Medicinal Products for Human Use opinion on Icotyde will be sent to the European Commission for an EU-wide marketing authorisation decision.
  • ▪A fourth phase 3 study evaluated Icotyde in patients with psoriasis affecting difficult-to-treat areas including the scalp, genital region, hands, and feet.

Topics

Drug Approval and Clinical TrialsDrug Policy, Pricing & Approval